Welcome to our dedicated page for MYOV news (Ticker: MYOV), a resource for investors and traders seeking the latest updates and insights on MYOV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MYOV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MYOV's position in the market.
Myovant Sciences (NYSE: MYOV) announced an update correcting the presentation time for CEO David Marek at the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on January 12, 2021, at 2:50 p.m. Eastern Time, not Pacific Time as previously stated. This event aims to showcase Myovant's commitment to redefining healthcare for women and men, particularly through its lead product, relugolix, approved for advanced prostate cancer. A live webcast will be available on their website.
Myovant Sciences (NYSE: MYOV) announced that David Marek, CEO, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 2:50 p.m. PT. A live webcast will be accessible on Myovant's website under the Investors & Media section.
Myovant focuses on redefining care for women and men, with its lead product candidate, relugolix, approved for advanced prostate cancer. The combination tablet for uterine fibroids is under regulatory review in Europe and the U.S., while MVT-602 is developed for female infertility.
Myovant Sciences (MYOV) has announced that ORGOVYX™ (relugolix), the first oral GnRH receptor antagonist approved by the FDA for advanced prostate cancer, is now available through authorized distributors. This follows its FDA approval on December 18, 2020. CEO David Marek emphasized the importance of quick access for patients and highlighted the ORGOVYX Support Program, which includes insurance support and a free trial of therapy for eligible patients. The commitment aims to establish a new standard of care for men suffering from advanced prostate cancer.
Myovant Sciences (NYSE: MYOV) has appointed David Marek as CEO, succeeding Lynn Seely. Marek brings over 30 years of biopharmaceutical experience, including roles at Amgen and Axsome Therapeutics. His expertise in commercial strategy positions Myovant for growth, particularly after receiving FDA approval for ORGOVYX™ and with a pending application for a relugolix combination tablet. The transition aims to strengthen Myovant's commercial performance as it evolves into a commercial-stage enterprise.
Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced a partnership to co-develop and commercialize ORGOVYX™ (relugolix) for advanced prostate cancer and a relugolix combination tablet for women's health in the U.S. and Canada. Myovant will receive an upfront payment of $650 million, with potential total payments reaching $4.2 billion through milestones. This collaboration aims to enhance the launch of ORGOVYX and expand Myovant's pipeline, addressing significant medical needs in oncology and women's health.
Myovant Sciences has received FDA approval for ORGOVYX™ (relugolix), the first oral gonadotropin-releasing hormone receptor antagonist for advanced prostate cancer. This decision, based on the Phase 3 HERO study, demonstrated a 96.7% testosterone suppression rate to castrate levels through 48 weeks. The drug, set for market availability in January 2021, aims to offer a safer alternative to current injectable therapies, with a lower incidence of cardiovascular events. Myovant is launching a patient support program to facilitate access for patients.
Myovant Sciences (NYSE: MYOV) has granted equity awards to 46 new employees on December 15, 2020, under its 2020 Inducement Plan, aligning with NYSE guidelines. The awards include a total of 126,800 restricted stock units (RSUs). The RSUs will vest over four years, with 25% vesting after one year and the remainder in quarterly installments, contingent on continued employment. Myovant is focused on innovative treatments for women's and men's health, including relugolix, currently under review for advanced prostate cancer and uterine fibroids.
Myovant Sciences (NYSE: MYOV) has announced participation in two upcoming investor conferences. On December 1, 2020, executives will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference at 4:45 p.m. Eastern time, followed by virtual one-on-one meetings. Also, Dr. Lynn Seely will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference with a pre-recorded presentation available at 10 a.m. Eastern time. These presentations can be accessed on Myovant's Investors & Media website section.
Myovant Sciences (NYSE: MYOV) announced the approval of equity awards for 72 new employees as part of the 2020 Inducement Plan. Effective November 15, 2020, these employees were granted restricted stock units (RSUs) amounting to 201,400 common shares. The RSUs vest in stages: one-fourth after one year, with the remaining shares vesting quarterly thereafter, contingent on continued employment. Myovant focuses on innovative treatments for men's and women's health, with its lead product candidate, relugolix, under regulatory review for prostate cancer and uterine fibroids.
Myovant Sciences (NYSE: MYOV) announced significant developments in its clinical programs and financial results for Q2 FY2020. The FDA is on track to review the NDA for relugolix monotherapy for advanced prostate cancer by December 20, 2020. Additionally, the NDA for the relugolix combination tablet for uterine fibroids is set for a decision by June 1, 2021. Phase 3 trial data shows promising efficacy and safety for both treatments. The net loss decreased to $67.1 million, while cash resources stand at $257.6 million, bolstered by a potential $200 million loan from Sumitomo Dainippon Pharma.
